Company Overview of Weill Cornell Medical College, New York
Weill Cornell Medical College, New York is an educational institution.
525 East 68th Street
New York, NY 10065
Key Executives for Weill Cornell Medical College, New York
Weill Cornell Medical College, New York does not have any Key Executives recorded.
Weill Cornell Medical College, New York Key Developments
Weill Cornell Medical College Announces Change of Chairman, Effective Jan. 1, 2015
Dec 9 14
After 20 years of bold and visionary leadership that has transformed Weill Cornell Medical College into a global healthcare enterprise, Sanford I. Weill will retire as chair of the Weill Cornell Board of Overseers on Jan. 1, 2015. Jessica M. Bibliowicz, a successful entrepreneur in the financial services business for nearly three decades, who has served on the Board of Overseers for the past decade, will succeed Mr. Weill, the new chair emeritus. In collaboration with medical college leadership, Ms. Bibliowicz will help lead Weill Cornell as it continues to break new ground in New York and abroad by expanding its clinical enterprise and forging public-private partnerships that accelerate groundbreaking scientific discoveries for patients. Working closely with Dr. Laurie H. Glimcher, the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College, Ms. Bibliowicz will help guide its transformation of medical education and drive dialogue on innovative healthcare delivery models that optimize the value and quality of patient care. Currently, Ms. Bibliowicz is a senior advisor at Bridge Growth Partners and serves on the board of directors of Sotheby's; Realogy; and the Asia Pacific Fund. She is a board director/trustee of Prudential Insurance Funds and is also on the board of Jazz at Lincoln Center.
Weill Cornell Medical College, New York Presents at Life Sciences Summit 2014, Oct-29-2014 01:15 PM
Oct 22 14
Weill Cornell Medical College, New York Presents at Life Sciences Summit 2014, Oct-29-2014 01:15 PM. Venue: 10 on the Park at Time Warner Center, 60 Columbus Circle, 10th Floor, New York, NY 10019, United States. Speakers: Ashish Raj, PhD, Associate Professor of Neuroscience, Brain Mind Research Institute.
OncoCyte Corporation and Cornell University Enter License Agreement to Accelerate Lung Cancer Diagnostic Product Development
May 27 14
BioTime Inc. and its subsidiary OncoCyte Corporation announced that OncoCyte has entered into a License Agreement with Cornell University through which Weill Cornell Medical College will provide blood samples derived from healthy people and lung cancer patients for comparative analysis using the company's proprietary PanC-Dx(TM) diagnostic tests. OncoCyte scientists will determine levels of tumor-associated gene expression in these samples, including assessing levels of its proprietary PanC-Dx(TM) cancer markers. The results of these analyses, along with the results of the nearly complete clinical study currently being conducted by OncoCyte's collaborators at The Wistar Institute, will be combined to produce a data set from over 700 patients. This data will be used by OncoCyte to assess the performance of potential cancer markers for the purpose of developing a multi-marker test for the detection of lung cancer. As part of the License, OncoCyte retains all rights to develop and market its proprietary lung cancer diagnostic products. PanC-Dx(TM) is a novel class of noninvasive cancer diagnostics that are based on a proprietary set of cancer markers characterized, in part, by broad expression patterns in numerous cancer types. The performance of the marker panel in determining the presence or the progression of disease in various categories of patients will determine the specific nature of the test to be developed and the approval pathway that OncoCyte will pursue.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|